Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Health Canada has approved CABTREO, a new triple-combination topical treatment for acne vulgaris in patients 12 years and older. Developed by Bausch Health (NYSE:BHC, TSX:BHC), CABTREO is the first and only triple-combination topical acne treatment approved in Canada, combining an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel has shown significant success in reducing both inflammatory and non-inflammatory acne lesions. CABTREO will be available in Canadian pharmacies in Q4 2024, offering a new option for millions of Canadians affected by acne.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, have announced the recipients of the 2024 Salix Gastrointestinal Health Scholars Program. For the fifth consecutive year, 10 students living with GI diseases will each receive a $10,000 scholarship to support their higher education. The awardees were selected from over 275 applications across four categories: Undergraduate Scholar Awards, Graduate Scholar Awards, Single Parent's Scholar Award, and Working Parent's Scholar Award.
The program aims to assist students who balance their academic pursuits with GI challenges. Applicants submitted essays describing their experiences and the role of their healthcare providers in their educational journey. An independent panel of judges reviewed all applications.
Bausch Health (NYSE:BHC) reported strong Q2 2024 results, with consolidated revenues of $2.40 billion, up 11% on a reported basis and 8% organically. The company achieved a GAAP Net Income of $10 million and Adjusted EBITDA of $798 million, up 10%. Key highlights include:
- Xifaxan® revenues grew 10% in the Salix segment
- International segment revenues increased 7%, with strong growth in Canada and Latin America
- Solta Medical segment revenues rose 16%, driven by growth in Asia-Pacific
- Bausch + Lomb segment revenues increased 17%, with organic growth across all business units
The company has raised its full-year Revenue and Adjusted EBITDA guidance. Bausch Health continues to focus on advancing its R&D pipeline, strengthening its balance sheet, and executing commercial strategies for global growth.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) has responded to market rumors circulating in a news article by Reorg®. The company categorically denies considering any form of bankruptcy or insolvency proceedings, contrary to the unsubstantiated claims made in the initial report. Reorg® has since updated its article to clarify that Bausch Health has not engaged in discussions with creditors regarding bankruptcy. The company maintains its policy of not commenting further on speculation, emphasizing the importance of relying on official company statements for accurate information about its financial status and future plans.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) has announced two new additions to its Executive Leadership Team. Jean-Jacques Charhon will join as Chief Financial Officer on August 19, 2024, bringing over 25 years of financial leadership experience from companies like General Electric, Hewlett Packard, Novartis, and Purdue Pharma. Aimee Lenar joined on July 15, 2024, as Executive Vice President, US Pharma, overseeing Salix Pharmaceuticals, Neurology, Generics, Market Access, and Commercial Operations. Lenar has over 20 years of pharmaceutical industry experience, most recently at Galderma.
CEO Thomas J. Appio expressed confidence that these appointments will drive the company's transformation towards becoming a globally integrated and innovative healthcare company. John Barresi, who served as Interim CFO, will resume his role as SVP, Controller.
Bausch Health Companies (NYSE:BHC, TSX:BHC) will announce its second quarter 2024 financial results on August 1, 2024. The company will hold a conference call and live webcast at 8:00 a.m. U.S. EST on the same day to discuss the results and provide a business update. All related materials will be available on the Investor Relations section of Bausch Health's website before the call begins. A replay of the conference call will be accessible on the investor relations website. Interested participants can register for the live Q&A session via a provided link.
Bausch Health announced that it has filed a patent infringement lawsuit against Norwich Pharmaceuticals in the U.S. District Court for the District of New Jersey. This action follows a Notice of Paragraph IV Certification received on May 10, 2024, from Norwich, indicating their submission of an amendment to an Abbreviated New Drug Application (ANDA) to the FDA. This amendment seeks approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets, used for treating diarrhea-predominant irritable bowel syndrome (IBS-D). Bausch Health has a history of defending its XIFAXAN® intellectual property, evidenced by a 2022 U.S. District Court ruling that blocked Norwich's first ANDA until October 2029. The company has since obtained additional patents related to XIFAXAN® 550 mg. Bausch Health is determined to protect its intellectual property and ensure patient safety and access to XIFAXAN®.
Bausch Health (NYSE:BHC) presented promising data from two recent clinical trials at major international healthcare conferences. At Digestive Disease Week 2024, Bausch Health shared positive results from a Phase 2 study of Amiselimod for treating mild to moderate ulcerative colitis. Both doses showed significant improvement in the Modified Mayo Score and higher rates of endoscopic improvement and clinical remission compared to placebo. Amiselimod was well-tolerated over the 12-week period.
Additionally, at the International Liver Congress 2024, Bausch Health presented pooled data analysis of Rifaximin for preventing overt hepatic encephalopathy (OHE) recurrence in cirrhosis patients. Rifaximin monotherapy significantly reduced the risk of OHE episodes and was well-tolerated compared to lactulose monotherapy.
Bausch Health, Canada announced additional public drug plan listings for PrUCERIS (budesonide) aerosol foam, expanding access for adults with mild to moderate distal ulcerative colitis. New listings include Alberta, Prince Edward Island, Newfoundland and Labrador, and federal plans for Indigenous people and Veterans. Previously, UCERIS was available in Ontario, Quebec, Saskatchewan, New Brunswick, and Nova Scotia. UCERIS, approved in Canada since September 2023, offers a unique glucocorticosteroid rectal foam for remission induction. Clinical trials showed superior efficacy over placebo in remission and rectal bleeding control at Week 6.
Bausch Health Companies (NYSE:BHC)(TSX:BHC) and its gastroenterology unit, Salix Pharmaceuticals, will present late-breaking data from a Phase 2 trial of Amiselimod for active ulcerative colitis (UC) at Digestive Disease Week 2024. The presentation, scheduled for May 19, 2024, in Washington D.C., will highlight Amiselimod's potential as an oral treatment for UC remission. The 12-week, double-blind, placebo-controlled study involved 320 patients and showed positive topline results, as announced in December 2023. The abstract, titled "Amiselimod for the treatment of active ulcerative colitis," authored by Stephen B. Hanauer et al., emphasizes Bausch's commitment to innovative UC therapies.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
